GlassScriptPhysician profile
Aaron Eli Bergsman
NPI 1720131048
$2,480.89
in general payments reported to CMS, 2019-2025
35 companies · $612 in 2025
The $612 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $405 · 2020: $161 · 2021: $125 · 2022: $234 · 2023: $528 · 2024: $416 · 2025: $612.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,556.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,555.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $579.62 | 2023-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Davol INC. | $379.79 | 2019-2023 | Phasix Mesh |
| Tela Bio, INC. | $219.33 | 2022-2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex), Ovitex 2s |
| W. L. Gore & Associates, INC. | $141.55 | 2019 | |
| Stryker Corporation | $131.38 | 2024 | 1788 |
| Smith+Nephew, INC. | $112.87 | 2024-2025 | Stravix Pl, Oasis |
| Takeda Pharmaceuticals U.S.A., INC. | $104.35 | 2022-2025 | Gattex |
| Biotissue Holdings INC. | $76.95 | 2024 | |
| Innocoll Pharmaceuticals Limited | $71.30 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $42.43 | 2021-2022 | |
| Servier Pharmaceuticals LLC | $39.64 | 2022-2023 | |
| Csl Behring | $36.94 | 2025 | Kcentra |
| Olympus America INC. | $35.77 | 2019-2021 | |
| Mimedx Group, INC. | $35.28 | 2024-2025 | |
| Shire North American Group INC | $32.99 | 2019 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $32.17 | 2022-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Boston Scientific Corporation | $31.93 | 2022-2023 | Varithena Administration Pack |
| Amneal Pharmaceuticals LLC | $28.79 | 2024 | Avastin |
| Stemline Therapeutics INC. | $26.59 | 2023 | Orserdu |
| Incyte Corporation | $26.56 | 2023 | Jakafi |
| Daiichi Sankyo INC. | $25.31 | 2023 | Enhertu |
| Polynovo North America LLC | $24.88 | 2025 | Novosorb Btm |
| Sanara Medtech INC. | $24.30 | 2025 | Celleraterx |
| Merck Sharp & Dohme LLC | $23.52 | 2024 | Keytruda |
| Seagen INC. | $22.47 | 2022 | |
| Taiho Oncology, INC. | $21.53 | 2021 | |
| Alnylam Pharmaceuticals INC. | $21.34 | 2023 | Givlaari |
| Eisai INC. | $20.25 | 2022 | |
| Acrotech Biopharma INC. | $18.12 | 2021 | |
| Janssen Pharmaceuticals, INC | $18.03 | 2022 | |
| Intuitive Surgical, INC. | $16.67 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $15.92 | 2021 | |
| Tetraphase Pharmaceuticals, INC. | $14.93 | 2019 | |
| Medline Industries LP | $14.29 | 2019 | |
| Teleflex LLC | $13.10 | 2023 | Deknatel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Bergsman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.